Literature DB >> 31705453

STING-Associated Vasculopathy with Onset in Infancy in Three Children with New Clinical Aspect and Unsatisfactory Therapeutic Responses to Tofacitinib.

Xiaolei Tang1, Hui Xu1, Chunju Zhou2, Yun Peng3, Hui Liu1, Jinrong Liu1, Huimin Li1, Haiming Yang1, Shunying Zhao4.   

Abstract

PURPOSE: STING-associated vasculopathy with onset in infancy (SAVI) is a new rare auto-inflammatory disease. The purpose of this study is to report new cases and summarize the manifestations and outcome of SAVI.
METHODS: We made a retrospective analysis of three pediatric patients diagnosed with SAVI between March 2016 and July 2018 in Beijing Children's Hospital.
RESULTS: Three patients comprised one boy and two girls. The median age of onset was 4 months. All patients had the same de novo heterozygous mutation (c.463G>A, p. V155M) of TMEM173. All patients presented with interstitial lung disease and one coexisted with diffuse alveolar hemorrhage. Rashes were presented in two patients. Other clinical manifestations include febrile attacks, failure to thrive, arthritis, myositis, cerebrovascular involvement, ureteral calculus, gastroesophageal reflux, and malnutrition. Ground-glass opacities were the most common features of chest computed tomography, followed with cysts and reticular opacities. Transbronchial lung biopsy was performed in one patient revealing pulmonary vasculitis. Skin biopsy was performed in one patient with changes of vasculitis. All patients were treated with corticosteroids and two patients received combined treatment of tofacitinib. The therapeutic effects of tofacitinib were limited on interstitial lung disease in both patients and were poor on rashes in one patient. One patient under the treatment of tofacitinib died.
CONCLUSIONS: New clinical aspect of diffuse alveolar hemorrhage is first reported to be associated with SAVI. Unsatisfactory therapeutic effects of tofacitinib are observed in this study and further evaluations are needed.

Entities:  

Keywords:  STING-associated vasculopathy with onset in infancy; child; diffuse alveolar hemorrhage; interstitial lung disease; tofacitinib

Mesh:

Substances:

Year:  2019        PMID: 31705453     DOI: 10.1007/s10875-019-00690-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.542


  23 in total

1.  First Egyptian patient with STING-associated vasculopathy with onset in infancy.

Authors:  W Shoman; Y El Chazli; I ElSawy; J I Aróstegui
Journal:  Scand J Rheumatol       Date:  2019-02-22       Impact factor: 3.641

2.  JAK inhibition in STING-associated interferonopathy.

Authors:  Mathieu P Rodero; Marie-Louise Frémond; Gillian I Rice; Bénédicte Neven; Yanick J Crow
Journal:  Ann Rheum Dis       Date:  2016-10-12       Impact factor: 19.103

3.  Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173.

Authors:  Jieun Seo; Jung-Ah Kang; Dong In Suh; Eun-Byeol Park; Cho-Rong Lee; Sun Ah Choi; Soo Yeon Kim; Yeji Kim; Sang-Heon Park; Michael Ye; Soon-Hak Kwon; June Dong Park; Byung Chan Lim; Dong Hun Lee; Suk-Jo Kang; Murim Choi; Sung-Gyoo Park; Jong-Hee Chae
Journal:  J Allergy Clin Immunol       Date:  2016-12-29       Impact factor: 10.793

4.  Activated STING in a vascular and pulmonary syndrome.

Authors:  Y Liu; A A Jesus; B Marrero; Z Deng; M Boehm; A S Paller; D Yang; S E Ramsey; G A Montealegre Sanchez; K Tenbrock; H Wittkowski; O Y Jones; H S Kuehn; C-C R Lee; M A DiMattia; E W Cowen; B Gonzalez; I Palmer; J J DiGiovanna; A Biancotto; H Kim; W L Tsai; A M Trier; Y Huang; D L Stone; S Hill; H J Kim; C St Hilaire; S Gurprasad; N Plass; D Chapelle; I Horkayne-Szakaly; D Foell; A Barysenka; F Candotti; S M Holland; J D Hughes; H Mehmet; A C Issekutz; M Raffeld; J McElwee; J R Fontana; C P Minniti; S Moir; D L Kastner; M Gadina; A C Steven; P T Wingfield; S R Brooks; S D Rosenzweig; T A Fleisher; R Goldbach-Mansky
Journal:  N Engl J Med       Date:  2014-07-16       Impact factor: 91.245

5.  Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.

Authors:  Marie-Louise Frémond; Mathieu Paul Rodero; Nadia Jeremiah; Alexandre Belot; Eric Jeziorski; Darragh Duffy; Didier Bessis; Guilhem Cros; Gillian I Rice; Bruno Charbit; Anne Hulin; Nihel Khoudour; Consuelo Modesto Caballero; Christine Bodemer; Monique Fabre; Laureline Berteloot; Muriel Le Bourgeois; Philippe Reix; Thierry Walzer; Despina Moshous; Stéphane Blanche; Alain Fischer; Brigitte Bader-Meunier; Fréderic Rieux-Laucat; Yanick Joseph Crow; Bénédicte Neven
Journal:  J Allergy Clin Immunol       Date:  2016-08-20       Impact factor: 10.793

6.  Interstitial Lung Disease Caused by STING-associated Vasculopathy with Onset in Infancy.

Authors:  Sarah L N Clarke; Elizabeth J Pellowe; Adriana A de Jesus; Raphaela Goldbach-Mansky; Tom N Hilliard; Athimalaipet V Ramanan
Journal:  Am J Respir Crit Care Med       Date:  2016-09-01       Impact factor: 21.405

7.  [Stimulator of interferon genes-associated vasculopathy with onset in infancy: first case report in China].

Authors:  Z X Yu; L Q Zhong; H M Song; C Y Wang; W Wang; J Li; M S Ma
Journal:  Zhonghua Er Ke Za Zhi       Date:  2018-03-02

8.  Type I interferon pathway activation in COPA syndrome.

Authors:  Stefano Volpi; Jessica Tsui; Marcello Mariani; Claudia Pastorino; Roberta Caorsi; Oliviero Sacco; Angelo Ravelli; Anthony K Shum; Marco Gattorno; Paolo Picco
Journal:  Clin Immunol       Date:  2017-10-10       Impact factor: 3.969

9.  Familial chilblain lupus due to a gain-of-function mutation in STING.

Authors:  Nadja König; Christoph Fiehn; Christine Wolf; Max Schuster; Emanuel Cura Costa; Victoria Tüngler; Hugo Ariel Alvarez; Osvaldo Chara; Kerstin Engel; Raphaela Goldbach-Mansky; Claudia Günther; Min Ae Lee-Kirsch
Journal:  Ann Rheum Dis       Date:  2016-08-26       Impact factor: 19.103

10.  Pro-inflammation Associated with a Gain-of-Function Mutation (R284S) in the Innate Immune Sensor STING.

Authors:  Hiroyasu Konno; Ivan K Chinn; Diana Hong; Jordan S Orange; James R Lupski; Alejandra Mendoza; Luis A Pedroza; Glen N Barber
Journal:  Cell Rep       Date:  2018-04-24       Impact factor: 9.423

View more
  12 in total

1.  Dysregulation of Type 1 Interferon Signaling in Systemic Sclerosis: a Promising Therapeutic Target?

Authors:  Minghua Wu; Shervin Assassi
Journal:  Curr Treatm Opt Rheumatol       Date:  2021-10-19

2.  Effectiveness and Safety of JAK Inhibitors in Autoinflammatory Diseases: A Systematic Review.

Authors:  Zhivana Boyadzhieva; Nikolas Ruffer; Gerd Burmester; Anne Pankow; Martin Krusche
Journal:  Front Med (Lausanne)       Date:  2022-06-27

3.  The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS.

Authors:  Kader Cetin Gedik; Lovro Lamot; Micol Romano; Erkan Demirkaya; David Piskin; Sofia Torreggiani; Laura A Adang; Thais Armangue; Kathe Barchus; Devon R Cordova; Yanick J Crow; Russell C Dale; Karen L Durrant; Despina Eleftheriou; Elisa M Fazzi; Marco Gattorno; Francesco Gavazzi; Eric P Hanson; Min Ae Lee-Kirsch; Gina A Montealegre Sanchez; Bénédicte Neven; Simona Orcesi; Seza Ozen; M Cecilia Poli; Elliot Schumacher; Davide Tonduti; Katsiaryna Uss; Daniel Aletaha; Brian M Feldman; Adeline Vanderver; Paul A Brogan; Raphaela Goldbach-Mansky
Journal:  Ann Rheum Dis       Date:  2022-01-27       Impact factor: 27.973

Review 4.  STING-Mediated Lung Inflammation and Beyond.

Authors:  Marie-Louise Frémond; Yanick J Crow
Journal:  J Clin Immunol       Date:  2021-02-02       Impact factor: 8.317

5.  Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling.

Authors:  Alice Lepelley; Maria José Martin-Niclós; Melvin Le Bihan; Joseph A Marsh; Carolina Uggenti; Gillian I Rice; Vincent Bondet; Darragh Duffy; Jonny Hertzog; Jan Rehwinkel; Serge Amselem; Siham Boulisfane-El Khalifi; Mary Brennan; Edwin Carter; Lucienne Chatenoud; Stéphanie Chhun; Aurore Coulomb l'Hermine; Marine Depp; Marie Legendre; Karen J Mackenzie; Jonathan Marey; Catherine McDougall; Kathryn J McKenzie; Thierry Jo Molina; Bénédicte Neven; Luis Seabra; Caroline Thumerelle; Marie Wislez; Nadia Nathan; Nicolas Manel; Yanick J Crow; Marie-Louise Frémond
Journal:  J Exp Med       Date:  2020-11-02       Impact factor: 14.307

Review 6.  Lung Inflammation in STING-Associated Vasculopathy with Onset in Infancy (SAVI).

Authors:  Clémence David; Marie-Louise Frémond
Journal:  Cells       Date:  2022-01-18       Impact factor: 6.600

7.  Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China.

Authors:  Wendao Li; Wei Wang; Wei Wang; Linqing Zhong; Lijuan Gou; Changyan Wang; Jingran Ma; Meiying Quan; Shan Jian; Xiaoyan Tang; Yu Zhang; Lin Wang; Mingsheng Ma; Hongmei Song
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

Review 8.  Intervention of cGAS‒STING signaling in sterile inflammatory diseases.

Authors:  Ze Hong; Jiahao Mei; Hanli Guo; Juanjuan Zhu; Chen Wang
Journal:  J Mol Cell Biol       Date:  2022-05-20       Impact factor: 8.185

9.  Rare Autoinflammatory Diseases.

Authors:  Özge Başaran; Yelda Bilginer; Seza Özen
Journal:  Turk Arch Pediatr       Date:  2022-01

Review 10.  Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity.

Authors:  Jérôme Hadjadj; Marie-Louise Frémond; Bénédicte Neven
Journal:  Front Immunol       Date:  2021-09-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.